# Exelixis, Inc. – Consensus ‘buy’ rating and 20.7% Upside Potential

- Link: https://www.directorstalkinterviews.com/exelixis-inc.consensus-buy-rating-and-20.7-upside-potential/4121130261
- Published: 2023-10-20T13:50:54+01:00
- Author: Charlotte Edwards

**Exelixis, Inc.** with ticker code (EXEL) have now 17 market analysts covering 
the stock. The analyst consensus now points to a rating of ‘buy’. The target price
High/Low ranges between 32 and 18 suggesting an average Analsyt target price of 
$25.76. Now with the previous closing price of $21.35 this indicates there is a 
potential upside of 20.7%. The 50 day MA is $21.78 and the 200 moving average now
moves to $19.40. The company has a market capitalization of 6.63B. The stock price
for the company is currently 20.83 USD

 The potential market cap would be $8,001,739,027 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 41.66, revenue per share of 5.3 
and a 2.93% return on assets.

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines
and combination regimens at the forefront of cancer care. It has four products, 
including its flagship molecule, cabozantinib, which is an inhibitor of multiple
tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved
as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and
in combination with Bristol-Myers Squibb Company’s (BMS) OPDIVO (nivolumab), for
hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated
thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic
medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor
of MEK approved as part of multiple combination regimens to treat specific forms
of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the
mineralocorticoid receptor (MR) approved the treatment of hypertension.

Share on: